Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22235405 | 0.77 | ALDH1A1 (0.33) | ALDH1A1TSHREPHX2CYP2D6CYP2C19 | |
| SCHEMBL21434073 | 0.77 | ALDH1A1 (0.36) | ALDH1A1TSHREPHX2CYP2D6CYP2C19 | |
| SCHEMBL26093858 | 0.76 | ALDH1A1 (0.31) | ALDH1A1TSHR | |
| SCHEMBL23539826 | 0.74 | ALDH1A1 (0.31) | ALDH1A1TSHR | |
| SCHEMBL21769866 | 0.73 | P2RX7 (0.59) | P2RX7P2RY12ALDH1A1EPHX2 | |
| SCHEMBL29478335 | 0.71 | HCRTR2 (0.45) | P2RX7P2RY12ALDH1A1TSHR | |
| SCHEMBL21434170 | 0.71 | ALDH1A1 (0.38) | ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL23354554 | 0.70 | CYP2D6 (0.32) | CYP2D6CYP2C19 | |
| SCHEMBL25251941 | 0.69 | GRM1 (0.47) | ALDH1A1TSHRCYP2C19 | |
| SCHEMBL11076664 | 0.67 | ALDH1A1 (0.70) | P2RX7ALDH1A1TSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4582422-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Global Health Drug Discovery Institute (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-20250214997-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) | 2025-07-03 | — | — | US | disclosed |
| WO-2024056099-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京华益健康药物研究中心 | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214997-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | METTL3, METTL14, METTL16 | P2RX7 4819/4885P2RY12 4735/4885ALDH1A1 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.